secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001396814-25-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039
--------------------------------------------------------------------------------

- Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.
- EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).
- Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.
- Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.
- Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/0001396814-25-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer